HLA-B and Stevens-Johnson syndrome: The HLA-B*15:02 allele is strongly associated with carbamazepine (CBZ)-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) (Chung et al., 2004; Chang et al., 2011; Tangamornsuksan et al., 2013; Phillips et al., 2018; Sung et al., 2020), therefore, the United States Food and Drug Administration (FDA) in 2007 recommended performing a pharmacogenomic test before starting drug treatment (Ferrell and McLeod, 2008).